Cork, Ireland, May 2022 – Irish diagnostics company Metabolomics Diagnostics announces its corporate partnership with the Preeclampsia Foundation.
The Preeclampsia Foundation is “training healthcare providers, educating patients and conducting and funding research to ensure hypertensive disorders no longer threaten the lives of mothers and their babies”.
Pre-eclampsia can cause premature birth, infant and maternal mortality and lead to lifelong health complications for mother and baby.
“Metabolomic Diagnostics is extremely happy to be partnering with Preeclampsia Foundation. Both are deeply committed to improving preeclampsia prediction by creating better tests that are more precise and less biased. We also believe in improving maternal health by educating and preventing bad outcomes. All women are different, and we want to cater to them all equally,” says Dr Ana Panigassi, Head of Clinical Affairs. “Our team wants to show results in the real world, and partners like the Preeclampsia Foundation are paramount to those efforts.”
More information is available at the Preeclampsia Foundation website at https://www.preeclampsia.org/corporate-partners.